Literature DB >> 11696270

Heart Failure with Normal Ejection Fraction.

Mauro Ortiz1, Gregory L. Freeman.   

Abstract

Heart failure with normal ejection fraction, also known as diastolic heart failure, is a major problem for patients and health-care providers and is a substantial expense to society. The main pathophysiologic processes involved are increased left ventricular stiffness and abnormal relaxation, with resulting impaired left ventricular filling. These processes typically displace the pressure-volume relationship in an upward direction, resulting in increased left ventricular end-diastolic, left atrial, and pulmonary capillary wedge pressures, leading to symptoms of pulmonary congestion. The most common clinical disorders leading to diastolic heart failure are 1) hypertension with concentric left ventricular hypertrophy, 2) coronary artery disease with decreased left ventricular compliance, 3) hypertrophic cardiomyopathy, and 4) aortic stenosis with concentric left ventricular hypertrophy. Echocardiography and cardiac catheterization with magnetic resonance imaging hold promise as future diagnostic tools. The approach to the treatment of diastolic heart failure is focused on four treatment goals: 1) persistent control of elevated blood pressure, with regression of left ventricular hypertrophy, 2) careful reduction of central blood volume (diuretics), 3) maintenance of atrial contraction and control of heart rate (beta-blockers, digoxin, atrioventricular pacing); and 4) improvement of left ventricular relaxation. There is currently no drug treatment specific for abnormal relaxation, although efforts are being made to develop such compounds. A promising future therapy includes agents that lyse advanced glycation end-products as an approach to relieving increased ventricular stiffness. In addition to pharmacotherapy, maintaining ideal body weight and a regular exercise program are also helpful in the treatment of diastolic heart failure. Although the overall prognosis of patients with diastolic dysfunction is more favorable than that of patients with systolic dysfunction, the frequency of treatment failure and recurrent symptoms underscores the need for further improvement in treatment of this condition.

Entities:  

Year:  2001        PMID: 11696270     DOI: 10.1007/s11936-001-0024-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  37 in total

1.  Defining diastolic heart failure: a call for standardized diagnostic criteria.

Authors:  R S Vasan; D Levy
Journal:  Circulation       Date:  2000-05-02       Impact factor: 29.690

2.  Effect of asynchrony on left ventricular relaxation.

Authors:  G R Heyndrickx; W J Paulus
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

3.  The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology.

Authors: 
Journal:  Eur Heart J       Date:  1997-05       Impact factor: 29.983

4.  Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study.

Authors:  A Mosterd; A W Hoes; M C de Bruyne; J W Deckers; D T Linker; A Hofman; D E Grobbee
Journal:  Eur Heart J       Date:  1999-03       Impact factor: 29.983

5.  Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group.

Authors:  J N Cohn; G Johnson
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

6.  Effect of aortic valve stenosis (pressure overload) and regurgitation (volume overload) on left ventricular systolic and diastolic function.

Authors:  B Villari; O M Hess; P Kaufmann; O N Krogmann; J Grimm; H P Krayenbuehl
Journal:  Am J Cardiol       Date:  1992-04-01       Impact factor: 2.778

7.  Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis.

Authors:  J S Silvestre; C Heymes; A Oubénaïssa; V Robert; B Aupetit-Faisant; A Carayon; B Swynghedauw; C Delcayre
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

8.  Effects of increasing afterload on early diastolic dysfunction in hypertrophic non-obstructive cardiomyopathy.

Authors:  G Hausdorf; V Siglow; C A Nienaber
Journal:  Br Heart J       Date:  1988-09

9.  Effects of spironolactone-altizide on left ventricular hypertrophy.

Authors:  S Degre; J M Detry; P Unger; J Cosyns; C Brohet; N Kormoss
Journal:  Acta Cardiol       Date:  1998       Impact factor: 1.718

Review 10.  Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management.

Authors:  R O Bonow; J E Udelson
Journal:  Ann Intern Med       Date:  1992-09-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.